DHP-B, a CPT1A inhibitor, disrupts CPT1A-VDAC1 interaction in the mitochondria, increasing mitochondrial permeability and reducing oxygen consumption and energy metabolism in CRC cells (Hu et al., 2023). This evidence concerns the gene VDAC1 and colorectal carcinoma.